Expert opinion on investigational drugs最新文献_第8页

Investigational agents for autosomal dominant polycystic kidney disease: preclinical and early phase study insights 常染色体显性多囊肾病的研究药物：临床前和早期阶段研究的启示

IF 6.1 2区医学

Expert opinion on investigational drugs Pub Date : 2024-04-15 DOI: 10.1080/13543784.2024.2342327

Irene Capelli, Sarah Lerario, Francesca Ciurli, Gian Marco Berti, Valeria Aiello, Michele Provenzano, Gaetano Manna

引用次数: 0

Sodium/Bile acid co-transporter inhibitors currently in preclinical or early clinical development for the treatment of primary biliary cholangitis 目前正处于临床前或早期临床开发阶段的钠/胆酸协同转运体抑制剂，用于治疗原发性胆汁性胆管炎

IF 6.1 2区医学

Expert opinion on investigational drugs Pub Date : 2024-04-13 DOI: 10.1080/13543784.2024.2343789

Abhishek Gairola, Aaron Wetten, Jessica Dyson

引用次数: 0

Investigational regenerative medicine for non-traumatic osteonecrosis of the femoral head: a survey of registered clinical trials. 治疗非创伤性股骨头坏死的再生医学研究：注册临床试验调查。

IF 6.1 2区医学

Expert opinion on investigational drugs Pub Date : 2024-04-01 Epub Date: 2024-03-05 DOI: 10.1080/13543784.2024.2326622

Yutaka Kuroda, Toshiyuki Kawai, Yaichiro Okuzu, Yugo Morita, Shuichi Matsuda

{"title":"Investigational regenerative medicine for non-traumatic osteonecrosis of the femoral head: a survey of registered clinical trials.","authors":"Yutaka Kuroda, Toshiyuki Kawai, Yaichiro Okuzu, Yugo Morita, Shuichi Matsuda","doi":"10.1080/13543784.2024.2326622","DOIUrl":"10.1080/13543784.2024.2326622","url":null,"abstract":"Introduction: Osteonecrosis of the femoral head (ONFH) is a refractory disease requiring joint replacement in young patients. Regenerative therapies have been developed.Areas covered: This study surveyed clinical trials on regenerative medicine for ONFH. We extracted clinical trials on non-traumatic ONFH from the websites of five publicly available major registries (EuropeanUnion Clinical Trials Register ([EU-CTR],ClinicalTrials.gov, Chinese ClinicalTrial Registry [ChiCTR], University Hospital Medical InformationNetwork - Clinical Trial Registry [UMIN-CTR] and Australian New Zealand Clinical Trials Registry [ANZCTR]).The trials were classified into six categories based on purpose: surgical treatment, non-drug conservative treatment, conservative drug treatment, therapeutic strategy, diagnosis and pathogenesis, and regenerative therapy.) We extracted 169 clinical trials on ONFH. Of these, 37 were on regenerative medicine, including 29 on cell therapy. Surgical treatment was the most common treatment, followed by regenerative therapy.There were 9 clinical trials registered in the EU-CTR, with 5 on regenerative medicine; 79 trials registered on ClinicalTrials.gov, with 24 on regenerativemedicine; 54 trials registered in the ChiCTR, with 6 on regenerative medicine.Expert opinion: The focus of the joint-preserving surgery has shifted to regenerative therapy based on using cell therapy in early-stage ONFH. The global standardisation of regenerative therapy is still ongoing.","PeriodicalId":12313,"journal":{"name":"Expert opinion on investigational drugs","volume":" ","pages":"405-414"},"PeriodicalIF":6.1,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140021305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Investigational drugs for the treatment of dysmenorrhea. 治疗痛经的研究药物。

IF 6.1 2区医学

Expert opinion on investigational drugs Pub Date : 2024-04-01 Epub Date: 2024-03-19 DOI: 10.1080/13543784.2024.2326627

Amelia K Mardon, Lucy Whitaker, Toobah Farooqi, Jane Girling, Claire Henry, Carolyn Ee, Jordan Tewhaiti-Smith, Mike Armour

{"title":"Investigational drugs for the treatment of dysmenorrhea.","authors":"Amelia K Mardon, Lucy Whitaker, Toobah Farooqi, Jane Girling, Claire Henry, Carolyn Ee, Jordan Tewhaiti-Smith, Mike Armour","doi":"10.1080/13543784.2024.2326627","DOIUrl":"10.1080/13543784.2024.2326627","url":null,"abstract":"Introduction: Dysmenorrhea is the most common cause of gynecological pain among women that has considerable impact on quality of life and psychosocial wellbeing. Non-steroidal anti-inflammatory drugs (NSAIDs) and hormonal therapies are most commonly used to treat dysmenorrhea. However, given these drugs are often associated with bothersome side effects and are less effective when there is an underlying cause contributing to dysmenorrhea (e.g. endometriosis), a patient-centered approach to managing dysmenorrhea is important. Various new drugs are currently being investigated for the treatment of primary and secondary dysmenorrhea.Areas covered: This review provides an updated overview on new therapeutic targets and investigational drugs for the treatment of primary and secondary dysmenorrhea. The authors describe the clinical development and implications of these drugs.Expert opinion: Among the investigative drugs discussed in this review, anti-inflammatories show the most promising results for the treatment of dysmenorrhea. However, given some trials have considerable methodological limitations, many drugs cannot be currently recommended. Research focused on understanding the mechanisms involved in menstruation and its associated symptoms will be important to identify new therapeutic targets for dysmenorrhea. Further robust clinical trials are required to better understand the efficacy and safety of investigational drugs for treating primary and secondary dysmenorrhea.","PeriodicalId":12313,"journal":{"name":"Expert opinion on investigational drugs","volume":" ","pages":"347-357"},"PeriodicalIF":6.1,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140021304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Novel preclinical developments of the primary sclerosing cholangitis treatment landscape. 原发性硬化性胆管炎治疗的临床前新进展。

IF 6.1 2区医学

Expert opinion on investigational drugs Pub Date : 2024-04-01 Epub Date: 2024-03-18 DOI: 10.1080/13543784.2024.2330738

Aalam Sohal, Kris V Kowdley

引用次数: 0

Investigational new drugs for the treatment of chronic renal failure: an overview of the literature. 治疗慢性肾功能衰竭的试验性新药：文献综述。

IF 6.1 2区医学

Expert opinion on investigational drugs Pub Date : 2024-04-01 Epub Date: 2024-03-28 DOI: 10.1080/13543784.2024.2326624

Chiara Terzo, Guido Gembillo, Valeria Cernaro, Elisa Longhitano, Vincenzo Calabrese, Chiara Casuscelli, Luigi Peritore, Domenico Santoro

{"title":"Investigational new drugs for the treatment of chronic renal failure: an overview of the literature.","authors":"Chiara Terzo, Guido Gembillo, Valeria Cernaro, Elisa Longhitano, Vincenzo Calabrese, Chiara Casuscelli, Luigi Peritore, Domenico Santoro","doi":"10.1080/13543784.2024.2326624","DOIUrl":"10.1080/13543784.2024.2326624","url":null,"abstract":"Introduction: Chronic kidney disease (CKD) is widespread throughout the world, with a high social and health impact. It is considered a 'silent killer' for its sudden onset without symptoms in the early stages of the disease. The main goal of nephrologists is to slow the progression of kidney disease and treat the associated symptoms with a range of new medications.Areas covered: The aim of this systematic review is to analyze the new investigational drugs for the treatment of chronic renal failure. Data were obtained from the available scientific literature and from the ClinicalTrials.gov website.Expert opinion: Among the drugs currently being researched, SGLT2 inhibitors appear to be the most promising drugs for the treatment of CKD, has they have slower progression of CKD and protection of cardiorenal function. An important role in the future of CKD treatment is played by autologous cell-therapy, which appears to be a new frontier in the treatment of CKD. Other therapeutic strategies are currently being investigated and have been shown to slow the progression of CKD. However, further studies are needed to determine whether these approaches may offer benefits in slowing the progression of CKD in the near future.","PeriodicalId":12313,"journal":{"name":"Expert opinion on investigational drugs","volume":" ","pages":"319-334"},"PeriodicalIF":6.1,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140012533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Microbiome modulators for atopic eczema: a systematic review of experimental and investigational therapeutics. 治疗特应性湿疹的微生物组调节剂：实验性和研究性疗法的系统综述。

IF 4.9 2区医学

Expert opinion on investigational drugs Pub Date : 2024-04-01 Epub Date: 2024-03-06 DOI: 10.1080/13543784.2024.2326625

Jonathan D Greenzaid, Lina J Chan, Brittany M Chandani, Nicholas R Kiritsis, Steven R Feldman

{"title":"Microbiome modulators for atopic eczema: a systematic review of experimental and investigational therapeutics.","authors":"Jonathan D Greenzaid, Lina J Chan, Brittany M Chandani, Nicholas R Kiritsis, Steven R Feldman","doi":"10.1080/13543784.2024.2326625","DOIUrl":"10.1080/13543784.2024.2326625","url":null,"abstract":"Introduction: Atopic dermatitis (AD) is a common inflammatory cutaneous disease that arises due to dysregulation of the Th2 immune response, impaired skin barrier integrity, and dysbiosis of the skin and gut microbiota. An abundance of Staphylococcus aureus biofilms in AD lesions increases the Th2 immune response, and gut bacteria release breakdown products such as Short Chain Fatty Acids that regulate the systemic immune response.Areas covered: We aim to evaluate therapies that modulate the microbiome in humans and discuss the clinical implications of these treatments. We performed a review of the literature in which 2,673 records were screened, and describe the findings of 108 studies that were included after full-text review. All included studies discussed the effects of therapies on the human microbiome and AD severity. Oral probiotics, topical probiotics, biologics, and investigational therapies were included in our analysis.Expert opinion: Oral probiotics demonstrate mixed efficacy at relieving AD symptoms. Topical probiotics reduce S. aureus abundance in AD lesional skin, yet for moderate-severe disease, these therapies may not reduce AD severity scores to the standard of biologics. Dupilumab and tralokinumab target key inflammatory pathways in AD and modulate the skin microbiome, further improving disease severity.","PeriodicalId":12313,"journal":{"name":"Expert opinion on investigational drugs","volume":" ","pages":"415-430"},"PeriodicalIF":4.9,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140039073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Early investigational agents for the treatment of benign prostatic hyperplasia'. 治疗良性前列腺增生症的早期研究药物"。

IF 6.1 2区医学

Expert opinion on investigational drugs Pub Date : 2024-04-01 Epub Date: 2024-03-04 DOI: 10.1080/13543784.2024.2326023

Stamatios Katsimperis, Konstantinos Kapriniotis, Ioannis Manolitsis, Themistoklis Bellos, Panagiotis Angelopoulos, Patrick Juliebø-Jones, Bhaskar Somani, Andreas Skolarikos, Lazaros Tzelves

{"title":"Early investigational agents for the treatment of benign prostatic hyperplasia'.","authors":"Stamatios Katsimperis, Konstantinos Kapriniotis, Ioannis Manolitsis, Themistoklis Bellos, Panagiotis Angelopoulos, Patrick Juliebø-Jones, Bhaskar Somani, Andreas Skolarikos, Lazaros Tzelves","doi":"10.1080/13543784.2024.2326023","DOIUrl":"10.1080/13543784.2024.2326023","url":null,"abstract":"Introduction: Benign prostatic hyperplasia (BPH), as a clinical entity that affects many people, has always been in the forefront of interest among researchers, pharmaceutical companies, and physicians. Patients with BPH exhibit a diverse range of symptoms, while current treatment options can occasionally cause adverse events. All the aforementioned have led to an increased demand for more effective treatment options.Areas covered: This review summarizes the outcomes of new medications used in a pre-clinical and clinical setting for the management of male lower urinary tract symptoms (LUTS)/BPH and provides information about ongoing trials and future directions in the management of this condition. More specifically, sheds light upon drug categories, such as reductase‑adrenoceptor antagonists, drugs interfering with the nitric oxide (NO)/cyclic guanosine monophosphate (GMP) signaling pathway, onabotulinumtoxinA, vitamin D3 (calcitriol) analogues, selective cannabinoid (CB) receptor agonists, talaporfin sodium, inhibitor of transforming growth factor beta 1 (TGF-β1), drugs targeting the hormonal control of the prostate, phytotherapy, and many more.Expert opinion: Clinical trials are being conducted on a number of new medications that may emerge as effective therapeutic alternatives in the coming years.","PeriodicalId":12313,"journal":{"name":"Expert opinion on investigational drugs","volume":" ","pages":"359-370"},"PeriodicalIF":6.1,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139989714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current experimental and early investigational agents for cardiac fibrosis: where are we at? 目前治疗心脏纤维化的试验性和早期研究药物：我们的进展如何？

IF 6.1 2区医学

Expert opinion on investigational drugs Pub Date : 2024-04-01 Epub Date: 2024-03-06 DOI: 10.1080/13543784.2024.2326024

Claudio M Ciampi, Andrea Sultana, Paolo Ossola, Andrea Farina, Gabriele Fragasso, Roberto Spoladore

{"title":"Current experimental and early investigational agents for cardiac fibrosis: where are we at?","authors":"Claudio M Ciampi, Andrea Sultana, Paolo Ossola, Andrea Farina, Gabriele Fragasso, Roberto Spoladore","doi":"10.1080/13543784.2024.2326024","DOIUrl":"10.1080/13543784.2024.2326024","url":null,"abstract":"Introduction: Myocardial fibrosis (MF) is induced by factors activating pro-fibrotic pathways such as acute and prolonged inflammation, myocardial ischemic events, hypertension, aging process, and genetically-linked cardiomyopathies. Dynamics and characteristics of myocardial fibrosis development are very different. The broad range of myocardial fibrosis presentations suggests the presence of multiple potential targets.Area covered: Heart failure treatment involves medications primarily aimed at counteracting neurohormonal activation. While these drugs have demonstrated efficacy against MF, not all specifically target inflammation or fibrosis progression with some exceptions such as RAAS inhibitors. Consequently, new therapies are being developed to address this issue. This article is aimed to describe anti-fibrotic drugs currently employed in clinical practice and emerging agents that target specific pathways, supported by evidence from both preclinical and clinical studies.Expert opinion: Despite various preclinical findings suggesting the potential utility of new drugs and molecules for treating cardiac fibrosis in animal models, there is a notable scarcity of clinical trials investigating these effects. However, the pathology of damage and repair in the heart muscle involves a complex network of interconnected inflammatory pathways and various types of immune cells. Our comprehension of the positive and negative roles played by specific immune cells and cytokines is an emerging area of research.","PeriodicalId":12313,"journal":{"name":"Expert opinion on investigational drugs","volume":" ","pages":"389-404"},"PeriodicalIF":6.1,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139996030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Antibacterial agents active against Gram Negative Bacilli in phase I, II, or III clinical trials. 在 I、II 或 III 期临床试验中对革兰氏阴性杆菌有效的抗菌剂。

IF 6.1 2区医学

Expert opinion on investigational drugs Pub Date : 2024-04-01 Epub Date: 2024-03-06 DOI: 10.1080/13543784.2024.2326028

David L Paterson

{"title":"Antibacterial agents active against Gram Negative Bacilli in phase I, II, or III clinical trials.","authors":"David L Paterson","doi":"10.1080/13543784.2024.2326028","DOIUrl":"10.1080/13543784.2024.2326028","url":null,"abstract":"Introduction: Antimicrobial resistance is a major threat to modern healthcare, and it is often regarded that the antibiotic pipeline is 'dry.'Areas covered: Antimicrobial agents active against Gram negative bacilli in Phase I, II, or III clinical trials were reviewed.Expert opinion: Nearly 50 antimicrobial agents (28 small molecules and 21 non-traditional antimicrobial agents) active against Gram-negative bacilli are currently in clinical trials. These have the potential to provide substantial improvements to the antimicrobial armamentarium, although it is known that 'leakage' from the pipeline occurs due to findings of toxicity during clinical trials. Significantly, a lack of funding for large phase III clinical trials is likely to prevent trials occurring for the indications most relevant to loss of life attributed to antimicrobial resistance such as ventilator-associated pneumonia. Non-traditional antimicrobial agents face issues in clinical development such as a lack of readily available and reliable susceptibility tests, and the potential need for superiority trials rather than non-inferiority trials. Most importantly, concrete plans must be made during clinical development for access of new antimicrobial agents to areas of the world where resistance to Gram negative bacilli is most frequent.","PeriodicalId":12313,"journal":{"name":"Expert opinion on investigational drugs","volume":" ","pages":"371-387"},"PeriodicalIF":6.1,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140039072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0